PT3181691T - Anticorpo anti-fcf23 e composição farmacêutica que o compreende - Google Patents

Anticorpo anti-fcf23 e composição farmacêutica que o compreende

Info

Publication number: PT3181691T
Authority: PT; Portugal
Prior art keywords: same; pharmaceutical composition; fgf23 antibody; anti fgf23; antibody
Prior art date: 2007-02-14

Application number

PT171521685T

Other languages

English (en)

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-14

Filing date

2008-02-14

Publication date

2020-08-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3181691(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-14 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2020-08-26 Publication of PT3181691T publication Critical patent/PT3181691T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Plant Pathology (AREA)

PT171521685T 2007-02-14 2008-02-14 Anticorpo anti-fcf23 e composição farmacêutica que o compreende PT3181691T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2007034018		2007-02-14

Publications (1)

Publication Number	Publication Date
PT3181691T true PT3181691T (pt)	2020-08-26

Family

ID=39690189

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT121709844T PT2502996T (pt)	2007-02-14	2008-02-14	Anticorpo anti-fgf23 e composição farmacêutica que o compreende
PT87117073T PT2128253E (pt)	2007-02-14	2008-02-14	Anticorpo anti-fgf23 e composição farmacêutica que o compreende
PT171521685T PT3181691T (pt)	2007-02-14	2008-02-14	Anticorpo anti-fcf23 e composição farmacêutica que o compreende

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT121709844T PT2502996T (pt)	2007-02-14	2008-02-14	Anticorpo anti-fgf23 e composição farmacêutica que o compreende
PT87117073T PT2128253E (pt)	2007-02-14	2008-02-14	Anticorpo anti-fgf23 e composição farmacêutica que o compreende

Country Status (22)

Country	Link
US (4)	US7883705B2 (pt)
EP (3)	EP2502996B1 (pt)
JP (1)	JP4800396B2 (pt)
KR (1)	KR101462291B1 (pt)
CN (2)	CN102702355B (pt)
AU (1)	AU2008215346B2 (pt)
CA (1)	CA2677782C (pt)
CY (3)	CY1118835T1 (pt)
DK (3)	DK2128253T3 (pt)
ES (3)	ES2811318T3 (pt)
FR (1)	FR18C1032I2 (pt)
HR (2)	HRP20170548T1 (pt)
HU (3)	HUE050517T2 (pt)
LT (3)	LT2502996T (pt)
LU (2)	LUC00082I2 (pt)
NL (1)	NL300945I2 (pt)
NO (1)	NO2018025I1 (pt)
PL (3)	PL3181691T3 (pt)
PT (3)	PT2502996T (pt)
SI (2)	SI3181691T1 (pt)
TW (1)	TWI422593B (pt)
WO (1)	WO2008099969A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1310554B1 (en) *	2000-08-11	2010-05-26	Kyowa Hakko Kirin Co., Ltd.	Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
ES2331414T3 (es) *	2001-12-28	2010-01-04	Kyowa Hakko Kirin Co Ltd	Anticuerpos contra el factor 23 de crecimiento de fibroblastos.
US7883705B2 (en) *	2007-02-14	2011-02-08	Kyowa Hakko Kirin Co., Ltd.	Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2012050673A1 (en) *	2010-10-14	2012-04-19	Wisconsin Alumni Research Foundation	Methods for the treatment of x-linked hypophosphatemia and related disorders
EP2723391B1 (en)	2011-06-24	2018-06-13	University of Miami	Fibroblast growth factor receptor inhibition for the treatment of disease
WO2015191312A1 (en) *	2014-06-09	2015-12-17	Ultragenyx Pharmaceutical Inc.	The effective and efficient control of serum phosphate for optimal bone formation
WO2018069232A1 (en)	2016-10-10	2018-04-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of having cardiac hypertrophy
JP7023932B2 (ja)	2017-03-30	2022-02-22	シスメックス株式会社	抗ＡｐｏＡ１抗体
JP2022527790A (ja) *	2019-03-29	2022-06-06	アターガ，エルエルシー	抗ｆｇｆ２３抗体分子
KR20250049545A (ko)	2022-08-10	2025-04-11	쿄와 기린 가부시키가이샤	항fgf23 항체 또는 해당 항체 단편
WO2024191781A2 (en) *	2023-03-10	2024-09-19	Ultragenyx Pharmaceutical Inc.	Human fgf23-binding antibodies with improved affinity and efficacy
CN119080938B (zh) *	2023-06-05	2025-06-24	东莞市朋志生物科技有限公司	抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
CN119954951A (zh) *	2024-12-31	2025-05-09	上海良润生物医药科技有限公司	iFGF23特异性抗体及其在制备慢性肾病辅助诊断试剂中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5623587A (en)	1979-08-03	1981-03-05	Mitsuwa Seiki Co Ltd	Vane type compressor
WO1985003934A1 (fr)	1984-03-06	1985-09-12	Takeda Chemical Industries, Ltd.	Proteine modifiee chimiquement et son procede de preparation
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61178926U (pt)	1985-04-23	1986-11-08
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
FI884924L (fi)	1987-10-28	1989-04-29	Oncogen	Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja)	1988-05-06	1999-10-06	住友製薬株式会社	ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5958879A (en)	1989-10-12	1999-09-28	Ohio University/Edison Biotechnology Institute	Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6001358A (en)	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
MXPA00011272A (es)	1998-05-18	2003-04-22	Univ London	Una novedosa fosfatonina de hormona polipeptida.
TWI255853B (en)	1998-08-21	2006-06-01	Kirin Brewery	Method for modifying chromosomes
AU3924300A (en)	1999-04-02	2000-10-23	Millennium Pharmaceuticals, Inc.	Fibroblast growth factor-20
US6596849B1 (en)	1999-05-28	2003-07-22	Academia Sinica	Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
CA2383254A1 (en)	1999-06-02	2000-12-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1690872A3 (en)	1999-12-01	2006-08-23	Genentech, Inc.	Composition and methods for the diagnosis of tumours
EP1252305A2 (en)	1999-12-08	2002-10-30	Genset	Full-length human cdnas encoding potentially secreted proteins
CA2396401A1 (en)	2000-01-05	2001-07-12	Zymogenetics, Inc.	Novel fgf homolog zfgf12
AU2001239765A1 (en)	2000-02-14	2001-08-27	Smith Kline Beecham Corporation	Novel compounds
AU3976701A (en)	2000-02-15	2001-08-27	Amgen, Inc.	Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en) *	2000-02-15	2006-07-20	Amgen Inc.	Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (en)	2000-03-08	2001-09-13	Chiron Corporation	Human fgf-23 gene and gene expression products
AU2001245535A1 (en)	2000-03-08	2001-09-17	Chiron Corporation	Human fgf-23 gene and gene expression products
ATE461213T1 (de)	2000-07-19	2010-04-15	Advanced Res & Tech Inst	Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP1310554B1 (en)	2000-08-11	2010-05-26	Kyowa Hakko Kirin Co., Ltd.	Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
WO2002076467A1 (en)	2001-03-22	2002-10-03	Genzyme Corporation	Compositions and methods to regulate bone and mineral metabolism
EP1381683A2 (en)	2001-04-26	2004-01-21	Geneprot, Inc.	Human fibroblast growth factor-related compositions
CN101508734A (zh) *	2001-04-27	2009-08-19	协和发酵麒麟株式会社	抗cd40单克隆抗体
ES2331414T3 (es)	2001-12-28	2010-01-04	Kyowa Hakko Kirin Co Ltd	Anticuerpos contra el factor 23 de crecimiento de fibroblastos.
US7094551B2 (en)	2002-09-17	2006-08-22	Zahradnik Richard J	Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
US20070036734A1 (en) *	2003-03-17	2007-02-15	Kirin Beer Kabushiki Kaisha	Therapeutic agent for periodontal disease
JP5139800B2 (ja) *	2004-06-03	2013-02-06	ノビミューンエスアー	抗ｃｄ３抗体およびその使用方法
US7476724B2 (en) *	2004-08-05	2009-01-13	Genentech, Inc.	Humanized anti-cmet antibodies
KR100918746B1 (ko) *	2004-09-06	2009-09-24	교와 핫꼬 기린 가부시키가이샤	항 ａ３３ 항체
WO2006078072A1 (ja)	2005-01-21	2006-07-27	Kirin Beer Kabushiki Kaisha	キメラ非ヒト動物およびその使用
US20100075375A1 (en)	2006-10-03	2010-03-25	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates
US20100062984A1 (en) *	2007-01-25	2010-03-11	Rajiv Kumar	Fgf-23 polypeptides
US7883705B2 (en) *	2007-02-14	2011-02-08	Kyowa Hakko Kirin Co., Ltd.	Anti FGF23 antibody and a pharmaceutical composition comprising the same

2008
- 2008-02-13 US US12/030,593 patent/US7883705B2/en active Active
- 2008-02-14 PT PT121709844T patent/PT2502996T/pt unknown
- 2008-02-14 AU AU2008215346A patent/AU2008215346B2/en active Active
- 2008-02-14 WO PCT/JP2008/052918 patent/WO2008099969A1/ja not_active Ceased
- 2008-02-14 ES ES17152168T patent/ES2811318T3/es active Active
- 2008-02-14 PL PL17152168T patent/PL3181691T3/pl unknown
- 2008-02-14 HU HUE17152168A patent/HUE050517T2/hu unknown
- 2008-02-14 CN CN201210161119.8A patent/CN102702355B/zh active Active
- 2008-02-14 LU LU00082C patent/LUC00082I2/en unknown
- 2008-02-14 KR KR1020097019085A patent/KR101462291B1/ko active Active
- 2008-02-14 SI SI200832131T patent/SI3181691T1/sl unknown
- 2008-02-14 CA CA2677782A patent/CA2677782C/en active Active
- 2008-02-14 DK DK08711707.3T patent/DK2128253T3/en active
- 2008-02-14 ES ES08711707T patent/ES2530670T3/es active Active
- 2008-02-14 EP EP12170984.4A patent/EP2502996B1/en active Active
- 2008-02-14 HU HUE12170984A patent/HUE031728T2/en unknown
- 2008-02-14 PT PT87117073T patent/PT2128253E/pt unknown
- 2008-02-14 LT LTEP12170984.4T patent/LT2502996T/lt unknown
- 2008-02-14 DK DK17152168.5T patent/DK3181691T3/da active
- 2008-02-14 ES ES12170984T patent/ES2625823T3/es active Active
- 2008-02-14 EP EP17152168.5A patent/EP3181691B1/en active Active
- 2008-02-14 PT PT171521685T patent/PT3181691T/pt unknown
- 2008-02-14 PL PL08711707T patent/PL2128253T3/pl unknown
- 2008-02-14 PL PL12170984T patent/PL2502996T3/pl unknown
- 2008-02-14 CN CN2008800048145A patent/CN101652476B/zh active Active
- 2008-02-14 LT LTEP17152168.5T patent/LT3181691T/lt unknown
- 2008-02-14 TW TW097105234A patent/TWI422593B/zh active
- 2008-02-14 EP EP08711707.3A patent/EP2128253B1/en active Active
- 2008-02-14 LU LU00081C patent/LUC00081I2/en unknown
- 2008-02-14 SI SI200831797T patent/SI2502996T1/sl unknown
- 2008-02-14 JP JP2008558165A patent/JP4800396B2/ja active Active
- 2008-02-14 DK DK12170984.4T patent/DK2502996T3/en active
2011
- 2011-02-02 US US13/019,557 patent/US9290569B2/en active Active
2016
- 2016-02-10 US US15/040,103 patent/US10202446B2/en active Active
2017
- 2017-04-04 HR HRP20170548TT patent/HRP20170548T1/hr unknown
- 2017-04-19 CY CY20171100446T patent/CY1118835T1/el unknown
2018
- 2018-07-27 NL NL300945C patent/NL300945I2/en unknown
- 2018-07-27 FR FR18C1032C patent/FR18C1032I2/fr active Active
- 2018-08-01 LT LTPA2018508C patent/LTC2502996I2/lt unknown
- 2018-08-02 HU HUS1800034C patent/HUS1800034I1/hu unknown
- 2018-08-07 CY CY2018021C patent/CY2018021I1/el unknown
- 2018-08-09 NO NO2018025C patent/NO2018025I1/no unknown
- 2018-12-18 US US16/223,930 patent/US20190106485A1/en not_active Abandoned
2020
- 2020-08-03 CY CY20201100713T patent/CY1123240T1/el unknown
- 2020-08-11 HR HRP20201266TT patent/HRP20201266T1/hr unknown

Also Published As

Publication number	Publication date
US9290569B2 (en)	2016-03-22
US10202446B2 (en)	2019-02-12
EP2502996A2 (en)	2012-09-26
AU2008215346B2 (en)	2013-01-10
EP2502996B1 (en)	2017-03-29
DK3181691T3 (da)	2020-08-17
TWI422593B (zh)	2014-01-11
CY2018021I2 (el)	2019-07-10
JP4800396B2 (ja)	2011-10-26
KR20090114452A (ko)	2009-11-03
US20110182913A1 (en)	2011-07-28
JPWO2008099969A1 (ja)	2010-05-27
NL300945I1 (en)	2018-08-15
HK1172917A1 (en)	2013-05-03
LT3181691T (lt)	2020-08-25
LUC00082I2 (pt)	2018-10-01
HRP20170548T1 (hr)	2017-08-25
CN102702355A (zh)	2012-10-03
DK2502996T3 (en)	2017-05-08
AU2008215346A1 (en)	2008-08-21
PT2128253E (pt)	2015-02-04
CA2677782C (en)	2016-07-26
CN101652476B (zh)	2012-07-04
PL2502996T3 (pl)	2017-07-31
ES2530670T3 (es)	2015-03-04
HK1140228A1 (en)	2010-10-08
EP2128253A1 (en)	2009-12-02
PT2502996T (pt)	2017-05-10
ES2811318T3 (es)	2021-03-11
PL3181691T3 (pl)	2020-11-02
FR18C1032I1 (pt)	2018-08-31
HUS1800034I1 (hu)	2018-09-28
LTC2502996I2 (lt)	2019-05-10
EP2502996A3 (en)	2013-04-10
PL2128253T3 (pl)	2015-04-30
TW200902549A (en)	2009-01-16
SI2502996T1 (sl)	2017-08-31
DK2128253T3 (en)	2015-01-05
CN102702355B (zh)	2014-09-24
US20190106485A1 (en)	2019-04-11
WO2008099969A1 (ja)	2008-08-21
EP2128253B1 (en)	2014-12-03
NL300945I2 (en)	2020-05-13
SI3181691T1 (sl)	2020-09-30
ES2625823T3 (es)	2017-07-20
EP2128253A4 (en)	2010-03-10
FR18C1032I2 (fr)	2019-08-09
LT2502996T (lt)	2017-06-26
CA2677782A1 (en)	2008-08-21
KR101462291B1 (ko)	2014-11-14
CY2018021I1 (el)	2019-07-10
HUE050517T2 (hu)	2020-12-28
HRP20201266T1 (hr)	2021-02-05
LUC00081I2 (pt)	2018-10-01
HUE031728T2 (en)	2017-07-28
NO2018025I1 (no)	2018-08-09
EP3181691B1 (en)	2020-07-15
LTPA2018508I1 (lt)	2018-09-10
CY1123240T1 (el)	2021-10-29
US20090148461A1 (en)	2009-06-11
EP3181691A1 (en)	2017-06-21
US20160159895A1 (en)	2016-06-09
CN101652476A (zh)	2010-02-17
CY1118835T1 (el)	2018-01-10
US7883705B2 (en)	2011-02-08

Publication	Publication Date	Title
SI3181691T1 (sl)	2020-09-30	Anti FGF23 protitelo in farmacevtski sestavek, ki ga vsebuje
HUS1800007I1 (hu)	2018-03-28	Gyógyászati készítmény
LT2436696T (lt)	2017-08-25	Anti-beta-amiloido antikūnas ir jo panaudojimas
IL196397A0 (en)	2011-08-01	Prlr-specific antibody and uses thereof
ZA200808862B (en)	2010-01-27	Flowable particulates
IL219268A (en)	2015-02-26	Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
EP2133095A4 (en)	2012-09-26	PHARMACEUTICAL COMPOSITION
EP2133094A4 (en)	2010-10-13	PHARMACEUTICAL COMPOSITION
IL200125A0 (en)	2010-04-15	Pharmaceutical composition
EP2224805A4 (en)	2013-10-16	PHARMACEUTICAL COMPOSITION
EP2224915A4 (en)	2014-01-22	PHARMACEUTICAL COMPOSITIONS
EP2224808A4 (en)	2013-11-27	PHARMACEUTICAL COMPOSITION
EP2070919A4 (en)	2010-05-05	SPIROCHINONE COMPOUND AND PHARMACEUTICAL COMPOSITION
EP2097074A4 (en)	2013-05-01	TOPICAL PHARMACEUTICAL COMPOSITION
EP2124959A4 (en)	2011-09-14	PHARMACEUTICAL COMPOSITION
IL205975A0 (en)	2010-11-30	Pharmaceutical composition
EP2114404A4 (en)	2010-03-03	COMPOUND AND PHARMACEUTICAL COMPOSITION
AP2734A (en)	2013-09-30	Pharmaceutical carrier composition and pharmaceutical composition
IL205931A0 (en)	2010-11-30	Pharmaceutical composition
GB0701295D0 (en)	2007-02-28	Z-stilbenes derivatives and the pharmaceutical composition thereof
GB0619768D0 (en)	2006-11-15	Pharmaceutical composition comprising antibodies
GB0612696D0 (en)	2006-08-09	Pharmaceutical composition
GB0600032D0 (en)	2006-02-08	Pharmaceutical composition
GB0617578D0 (en)	2006-10-18	Pharmaceutical composition
GB0614457D0 (en)	2006-08-30	Pharmaceutical Combinations